Shanxi and China Biotech jointly build a vaccine joint research and development center

Source: Pharmaceutical Network

Medicine News June 30th, on the evening of the 28th, the Shanxi Provincial People's Government and China Biotechnology Co., Ltd. (hereinafter referred to as "China Bio") signed a framework agreement to jointly build a vaccine joint research and development center and a vaccine clinical research base.

Wu Wei, vice governor of Shanxi Province, said that in the past five years, Shanxi and China Biology have cooperated in more than 10 phase III/IV clinical trials of vaccines. The cooperation between the two parties to jointly establish a vaccine joint research and development center and a vaccine clinical research base is of great significance for promoting the development and production capacity of Shanxi vaccines and specific drugs.

In recent years, China Biotechnology has carried out three vaccine clinical projects in the Shanxi Provincial Center for Disease Control. Among them, the quadrivalent influenza vaccine has passed the technical review of the drug regulatory department and the clinical and production site verification; the quadrivalent meningopolysaccharide vaccine has been declared for production; the quadrivalent cervical cancer vaccine has completed the entire immunization.

The Shanxi Provincial Center for Disease Control and Prevention is one of the earliest institutions that conducted clinical trials of vaccines in China. China Biotech is a domestic leader in vaccine research and development, production, and distribution. Effectiveness evaluation, epidemiological investigation, adverse reaction monitoring, prevention and control of new and emerging infectious diseases, etc., exerted their respective advantages and developed together.

China's biological business scope covers six major bioproducts fields: human vaccines, blood products, medical cosmetics, animal health, antibody drugs, and medical diagnosis. Human vaccines can produce 50 kinds of vaccines annually, with an annual output exceeding 700 million doses, providing more than 80% of vaccines for national immunization programs; the annual plasma collection volume exceeds 2000 tons, and 11 blood products are in production.

"Further strengthen exchanges and cooperation and promote comprehensive cooperation between the two parties in various fields." Yang Xiaoming, chairman of China Bio said that through the construction of a clinical vaccine research base and a joint vaccine research center, efforts will be made to promote the development of new vaccines and the transformation of scientific and technological achievements. Continue to increase investment in Shanxi.

China Biology is responsible for the production and supply of more than 90% of vaccines for immunization planning in Shanxi, and has provided Shanxi with more than 200 million doses of various vaccines. "China Biotech is willing to reorganize and acquire Shanxi Kangbao Biological Products Co., Ltd. and make additional investment to expand its blood product production capacity." Yang Xiaoming introduced that the overall investment is expected to exceed 1 billion yuan.

Wu Wei said that Shanxi is ready to carry out comprehensive, multi-field and deep-level exchanges and cooperation under the framework agreement between the two sides, and will support it in policy support, supporting investment, talent protection, etc. to ensure that it includes elderly people over 60 years old. Many Huimin cooperative projects including free inoculation of 23-valent pneumonia vaccine and new coronary pneumonia vaccine emergency inoculation have been implemented.